Abstract
Transport proteins play an important role in the adsorption, distribution and elimination of a wide variety of drugs. Therefore, it is not surprising that transporter-based drug interactions can occur in the clinic. These interactions can lead to changes in toxicity and/or efficacy of the affected drug. Here, we review such interactions and ask if these interactions could have been predicted from in vitro data. Conducting such in vitro-in vivo correlation is important for predicting future transporter-based drug interactions.
Publication types
-
Comparative Study
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
ATP-Binding Cassette Transporters / antagonists & inhibitors
-
ATP-Binding Cassette Transporters / metabolism*
-
Animals
-
Anti-Arrhythmia Agents / pharmacokinetics
-
Anti-Arrhythmia Agents / pharmacology*
-
Digoxin / pharmacokinetics
-
Drug Interactions*
-
Gemfibrozil / pharmacology
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics
-
Hypolipidemic Agents / pharmacokinetics
-
Hypolipidemic Agents / pharmacology*
-
In Vitro Techniques
-
Kidney / drug effects
-
Kidney / metabolism
-
Liver / drug effects
-
Liver / metabolism
-
Membrane Transport Proteins / metabolism
-
Models, Biological
-
Organic Anion Transporters / antagonists & inhibitors
-
Organic Anion Transporters / metabolism
-
Organic Cation Transport Proteins / metabolism
-
Quinidine / pharmacology
Substances
-
ATP-Binding Cassette Transporters
-
Anti-Arrhythmia Agents
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypolipidemic Agents
-
Membrane Transport Proteins
-
Organic Anion Transporters
-
Organic Cation Transport Proteins
-
Digoxin
-
Quinidine
-
Gemfibrozil